Supernus Posts Exciting Clinical Data Regarding Trokendi XR(TM) and Oxtellar XR(TM) on the Company Website

Supernus Posts Exciting Clinical Data Regarding Trokendi XR(TM) and Oxtellar
XR(TM) on the Company Website

ROCKVILLE, Md., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that
the clinical data that was released at the American Epilepsy Society (AES)
Meeting in December in Washington DC is now available on its website. Please
click here to view.

In total, Supernus had 12 presentations/scientific posters highlighting data
that were generated on Trokendi XR and Oxtellar XR. For a complete read on the
data and scientific posters please refer to the link above or go to our
website under the investor and events & presentations section.

Some of the key and exciting highlights from the data include:

Trokendi XR™:

An overwhelming majority of patients (93%) preferred once daily Trokendi XR
when switched from twice daily immediate release topiramate. Similarly, 92% of
the patients with epilepsy also expect Trokendi XR to have a positive impact
on treatment adherence.

In a head to head study, once daily Trokendi XR was bioequivalent to twice
daily immediate release topiramate and showed a potential pharmacodynamic
difference with a significantly less negative impact on objective measures of
cognitive function such as verbal fluency (i.e., Controlled Oral Word
Association, COWA).

Trokendi XR offers the convenience of once-daily topiramate dosing without
increasing the clinical risk of missed, delayed, or doubled doses.

Co-administration of Trokendi XR with alcohol in humans does not result in
"dose dumping." Patients will have similar systemic exposure whether Trokendi
XR is taken with or without alcohol.

Dosage recommendations for Trokendi XR in elderly patients are the same as for
immediate release topiramate , i.e., reduce dose according to renal function
status rather than age (one-half the adult dose if creatinine clearance<
70mL/min/1.73m^2).

Oxtellar XR™:

Seizure control achieved with once-daily Oxtellar XR during the double-blind
PROSPER study was maintained and further improved during the long term
open-label extension when dosages could be optimized. Oxtellar XR showed
impressive median % seizure reduction up to 64% with responder rates (% of
patients with > 50% seizure reduction) overtime up to 61%.

Oxtellar XR was very well tolerated during long-term maintenance therapy with
discontinuations due to adverse events of only 5%. Such improved tolerability
may allow higher and potentially more effective Oxcarbazepine dosages to be
achieved with once daily Oxtellar XR.

About Trokendi XR™

Trokendi XR is the only approved novel once-daily extended release formulation
of topiramate for the treatment of epilepsy. Trokendi XR is an antiepileptic
drug indicated for initial monotherapy in patients 10 years of age and older
with partial onset or primary generalized tonic-clonic seizures; adjunctive
therapy in patients 6 years of age and older with partial onset or primary
generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years
of age and older with seizures associated with Lennox-Gastaut syndrome. The
product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.

For full prescribing and safety information, click here.

About Oxtellar XR™

Oxtellar XR is the only approved novel once- daily extended release
formulation of oxcarbazepine for the treatment of epilepsy. It is an
antiepileptic drug indicated for adjunctive therapy in the treatment of
partial seizures in adults and in children 6 to 17 years of age. The product
is available in 150 mg, 300 mg and 600 mg extended-release tablets.

For full prescribing and safety information, click here.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward Looking Statements

This press release contains forward-looking statements regarding clinical data
and the potential for Trokendi XR and Oxtellar XR to treat epilepsy. Actual
results may differ materially from those in these forward-looking statements
as a result of various factors, including, but not limited to, risks regarding
the company's ability to commercialize the product successfully, whether
physicians will prescribe and patients will use the product, and competition
in the market. For a further description of these and other risks facing the
Company, please see the risk factors described in the Company's Annual Report
Form 10-K that was filed with the United States Securities and Exchange
Commission on March 15, 2013 and under the caption "Risk Factors" and the
updates to these risk factors in the Company's quarterly report form 10-Q that
was filed with the Commission on August 15, 2013. Forward-looking statements
speak only as of the date of this press release, and the company undertakes no
obligation to update or revise these statements, except as may be required by
law.

CONTACT: Jack A. Khattar, President and CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
 
Press spacebar to pause and continue. Press esc to stop.